Drug Delivery Platforms
•229 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (229)
| Company | Market Cap | Price |
|---|---|---|
|
BCYC
Bicycle Therapeutics plc
Platform enables targeted delivery and payload conjugation for therapeutics (drug delivery platform).
|
$369.73M |
$5.33
+3.79%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 employs a gut-restricted prodrug delivery approach, representing a Drug Delivery Platforms technology.
|
$357.61M |
$2.40
+2.79%
|
|
DMAC
DiaMedica Therapeutics Inc.
DM199 represents a drug-delivery/therapeutic platform with IV administration and ongoing manufacturing development.
|
$356.73M |
$6.86
+3.55%
|
|
SLN
Silence Therapeutics plc
Platform-based drug delivery (GalNAc-siRNA) enabling targeted delivery for siRNA therapies.
|
$355.32M |
$7.53
-0.92%
|
|
CADL
Candel Therapeutics, Inc.
enLIGHTEN HSV-based platform represents a drug delivery platform used to design and optimize viral immunotherapies.
|
$349.70M |
$6.38
+23.64%
|
|
EDIT
Editas Medicine, Inc.
Drug Delivery Platforms: proprietary delivery platform (tLNP) enabling in vivo gene editing.
|
$340.69M |
$3.49
+4.18%
|
|
CLPT
ClearPoint Neuro, Inc.
SmartFlow cannula represents a drug-delivery platform for targeted brain infusion, tied to cell/gene therapy delivery approaches.
|
$335.11M |
$11.79
+12.29%
|
|
CATX
Perspective Therapeutics, Inc.
Developing a drug-delivery platform around the 212Pb radiopharmaceuticals and regional finishing capabilities.
|
$312.22M |
$4.24
-0.59%
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK represents a drug-delivery platform concept (off-the-shelf cell therapy) enabling administration of therapy.
|
$308.04M |
$12.50
+3.22%
|
|
SCPH
scPharmaceuticals Inc.
Drug Delivery Platforms is a core technology enabling the subcutaneous administration of FUROSCIX.
|
$299.33M |
$5.67
|
|
ALEC
Alector, Inc.
Alector Brain Carrier (ABC) is a proprietary drug delivery platform to enhance brain exposure and enable subcutaneous administration.
|
$280.52M |
$2.57
+0.78%
|
|
STRO
Sutro Biopharma, Inc.
XpressCF+/ADC platform constitutes a drug delivery platform used to create and optimize ADCs.
|
$268.60M |
$31.64
+7.80%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
Virtue SAB represents a drug-delivery platform delivering extended-release sirolimus to the vessel wall.
|
$258.61M |
$4.58
+2.46%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Core technology platforms STARR sa-mRNA and LUNAR delivery system enabling RNA therapeutics.
|
$251.45M |
$8.87
+0.34%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$232.33M |
$4.64
+3.45%
|
|
VYGR
Voyager Therapeutics, Inc.
ALPL-based non-viral shuttle and TRACER capsids represent a Drug Delivery Platforms technology.
|
$229.63M |
$4.13
+4.29%
|
|
QNCX
Quince Therapeutics, Inc.
Quince's AIDE platform is a drug-delivery platform encapsulating drugs in autologous red blood cells.
|
$226.67M |
$4.28
-2.73%
|
|
RNA
Atrium Therapeutics, Inc.
Drug Delivery Platforms: AOC platform is a delivery technology for targeting oligonucleotides to specific tissues.
|
$223.57M |
$14.40
+2.64%
|
|
TARA
Protara Therapeutics, Inc.
IV Choline Chloride is described as a platform for phospholipid substrate replacement, i.e., a Drug Delivery Platform.
|
$209.91M |
$5.44
+6.04%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Drug delivery platforms tag fits the proprietary plant virus nanoparticle delivery technology used to modulate immune responses.
|
$208.72M |
$0.52
|
|
SLGL
Sol-Gel Technologies Ltd.
Proprietary microencapsulation drug-delivery platform is a core technology Sol-Gel uses to formulate topical therapies.
|
$205.79M |
$74.82
-0.66%
|
|
ADAG
Adagene Inc.
Drug Delivery Platforms capturing the platform-based approach to activating antibodies in tumors.
|
$195.03M |
$3.79
-8.57%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$183.36M |
$1.00
+6.91%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's nasal spray represents a drug delivery platform/format for self-administration.
|
$178.86M |
$2.11
+0.96%
|
|
VXRT
Vaxart, Inc.
The VAAST platform constitutes a Drug Delivery Platform enabling oral, needle-free vaccines with mucosal immunity and room-temperature stability.
|
$170.96M |
$0.75
|
|
REPL
Replimune Group, Inc.
RPx platform functions as a drug delivery platform enabling multi-gene payload immunotherapies.
|
$170.22M |
$2.17
-0.91%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA utilizes an intranasal delivery method for Foralumab, representing a Drug Delivery Platforms approach.
|
$169.24M |
$1.25
-7.09%
|
|
MOLN
Molecular Partners AG
DARPin platform represents a drug-delivery/modular platform enabling targeted biologics.
|
$157.26M |
$4.29
+2.63%
|
|
BMEA
Biomea Fusion, Inc.
Platform technology (FUSION System) used to discover/develop covalent small molecule drugs, representing a drug discovery platform.
|
$156.26M |
$2.21
+14.25%
|
|
THTX
Theratechnologies Inc.
SORT1+ Technology platform functions as a drug-delivery platform enabling peptide-drug conjugates.
|
$155.87M |
$3.39
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$154.43M |
$3.88
+0.52%
|
|
MRSN
Mersana Therapeutics, Inc.
Dolasynthen and Immunosynthen platforms are drug delivery platforms enabling targeted ADC payload delivery.
|
$145.13M |
$29.10
+0.07%
|
|
ELTX
Elicio Therapeutics, Inc.
AMP platform described as a drug delivery platform targeting lymph nodes.
|
$144.76M |
$8.74
-1.35%
|
|
IKT
Inhibikase Therapeutics, Inc.
Prodrug technology used in IKT-001Pro represents a drug-delivery platform approach.
|
$137.57M |
$1.81
+6.76%
|
|
PEPG
PepGen Inc.
The Enhanced Delivery Oligonucleotide (EDO) platform represents a drug delivery technology, justifying the Drug Delivery Platforms tag.
|
$116.87M |
$1.72
+2.69%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$116.21M |
$0.96
+4.11%
|
|
ASRT
Assertio Holdings, Inc.
Sympazan's PharmFilm technology and related drug-delivery approaches indicate a Drug Delivery Platforms capability.
|
$115.57M |
$18.02
|
|
ALDX
Aldeyra Therapeutics, Inc.
RASP modulation platform described as a drug-delivery/platform technology.
|
$108.29M |
$1.81
+0.56%
|
|
GNLX
Genelux Corporation
CHOICE is a platform-based drug delivery approach for immunotherapies, fitting Drug Delivery Platforms.
|
$106.16M |
$2.79
+0.54%
|
|
ACOG
Alpha Cognition Inc. Common Stock
The company references sublingual and coated tablet formulations, indicating a drug delivery platform focus.
|
$105.05M |
$6.50
+5.18%
|
|
NTHI
Neonc Technologies Holdings, Inc.
Proprietary drug delivery platform enabling brain tumor targeting and BBB bypass; platform used for delivery of therapeutics.
|
$103.99M |
$5.29
+5.38%
|
|
PYXS
Pyxis Oncology, Inc.
MICVO employs a drug-delivery platform approach (extracellular matrix targeting with a cleavable linker and cytotoxic payload).
|
$103.36M |
$1.67
-2.06%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$103.23M |
$0.44
+1.60%
|
|
ADVM
Adverum Biotechnologies, Inc.
The program relies on a proprietary drug delivery platform (vector-based) for sustained expression of a therapeutic protein.
|
$91.49M |
$4.38
+0.34%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX2004 leverages a proprietary linker-payload platform, aligning with the Drug Delivery Platforms category.
|
$90.54M |
$1.68
-0.30%
|
|
SGMO
Sangamo Therapeutics, Inc.
STAC-BBB represents a CNS drug-delivery platform enabling systemic delivery across the blood-brain barrier.
|
$88.16M |
$0.25
-7.96%
|
|
ATHE
Alterity Therapeutics Limited
Alterity's iron chaperone platform represents a drug-delivery/platform technology that redistributes iron to modulate disease pathways.
|
$81.60M |
$4.34
+9.32%
|
|
MCRB
Seres Therapeutics, Inc.
MbTx Platform is Seres' core drug-delivery platform enabling the design and cultivation of targeted live biotherapeutic consortia.
|
$80.42M |
$8.87
+0.45%
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$74.65M |
$1.30
+3.17%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$74.20M |
$4.71
+1.18%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$65.21M |
$6.40
+0.79%
|
|
INO
Inovio Pharmaceuticals, Inc.
CELLECTRA delivery technology represents a drug delivery platform enabling in vivo DNA plasmid delivery.
|
$63.75M |
$1.20
+3.02%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$60.61M |
$4.29
+4.13%
|
|
VRCA
Verrica Pharmaceuticals Inc.
YCANTH uses a proprietary drug-device combination applicator, aligning with a drug delivery platform.
|
$59.98M |
$6.42
+3.30%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$58.70M |
$1.27
+6.25%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$51.75M |
$4.08
-0.37%
|
|
OSTX
OS Therapies Incorporated
Drug Delivery Platforms tag captures the tunable linker/ delivery platform used in OST-tADC.
|
$48.95M |
$1.39
-1.07%
|
|
CUE
Cue Biopharma, Inc.
Immuno-STAT represents a drug delivery platform for targeted, injectable biologics.
|
$47.73M |
$0.61
-1.43%
|
|
IBIO
iBio, Inc.
ShieldTx and related antibody engineering imply a Drug Delivery Platform approach to spatially control activity.
|
$46.32M |
$2.06
-2.61%
|
|
HOWL
Werewolf Therapeutics, Inc.
PREDATOR platform represents a drug delivery platform enabling tumor-selective activation.
|
$45.90M |
$0.94
+2.62%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$42.15M |
$2.98
+9.37%
|
|
NMTC
NeuroOne Medical Technologies Corporation
sEEG-based drug delivery system platform enabling localized therapeutic delivery from neural implants.
|
$40.67M |
$4.83
+5.58%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
ARC/Radiopharmaceutical platform represents a drug delivery platform enabling targeted radiotherapy.
|
$40.55M |
$1.31
+4.80%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide functions as a drug-delivery platform to enhance tumor penetration and co-administered therapies.
|
$39.23M |
$4.41
-1.67%
|
|
PASG
Passage Bio, Inc.
PBFT02 leverages a drug delivery platform (AAV1/ICM) to deliver progranulin to the CNS.
|
$37.10M |
$12.02
+2.91%
|
|
GBIO
Generation Bio Co.
ctLNP is a proprietary drug delivery platform enabling targeted, redosable delivery of nucleic acids.
|
$35.97M |
$5.36
+0.37%
|
|
MURA
Mural Oncology plc
Engineered cytokine platform underlying the programs represents a Drug Delivery Platform/therapeutic delivery approach.
|
$35.34M |
$2.03
-0.49%
|
|
XLO
Xilio Therapeutics, Inc.
Drug Delivery Platforms reflects Xilio's tumor-activation masking technology designed to localize activity within tumors.
|
$32.14M |
$8.58
+2.75%
|
|
ELUT
Elutia Inc.
EluPro embodies a Drug Delivery Platform delivering antibiotics from the biomatrix at the implant site.
|
$29.59M |
$0.70
-0.37%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell and TVGN platform described as a drug delivery platform enabling cell therapies.
|
$29.33M |
$7.42
+16.59%
|
|
BTAI
BioXcel Therapeutics, Inc.
Sublingual film formulation BXCL501 represents a drug-delivery platform; included as Drug Delivery Platforms.
|
$29.26M |
$2.04
-1.69%
|
|
NXTC
NextCure, Inc.
NextCure’s ADC technology represents a drug delivery platform that enables targeted payload delivery to tumors.
|
$27.67M |
$10.28
-6.55%
|
|
RNTX
Rein Therapeutics Inc.
LTI-3.00 employs a dry powder inhalation delivery approach, representing a Drug Delivery Platforms category.
|
$26.57M |
$1.16
-3.33%
|
|
AYTU
Aytu BioPharma, Inc.
The company employs a Time Release Resin Particle (TRRP) proprietary technology, aligning with the 'Drug Delivery Platforms' category.
|
$26.49M |
$2.59
+0.39%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$25.63M |
$1.02
+4.06%
|
|
VTGN
VistaGen Therapeutics, Inc.
Pherine platform represents a non-systemic intranasal drug-delivery approach developed by the company.
|
$24.79M |
$0.64
+5.52%
|
|
THAR
Tharimmune, Inc.
TH023 leverages external oral-delivery platforms (Soteria/Phloral) via Intract, representing a Drug Delivery Platform technology.
|
$23.83M |
$4.74
-5.58%
|
|
AKTX
Akari Therapeutics, Plc
Drug delivery platforms conceptually underpin the novel ADC payloads and linker technologies.
|
$20.35M |
$0.28
-31.68%
|
|
TLPH
Talphera, Inc.
The company emphasizes drug delivery platform concepts through lyophilized nafamostat formulations and IV/compounded administration approaches.
|
$18.71M |
$0.91
-2.03%
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$17.07M |
$10.98
+0.32%
|
|
SER
Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
|
$16.09M |
$1.50
-4.78%
|
|
OTLC
Oncotelic Therapeutics, Inc.
Nanoparticle-based delivery platform for six anticancer agents constitutes a Drug Delivery Platform.
|
$15.13M |
$0.04
|
|
JUNS
Jupiter Neurosciences, Inc.
Drug Delivery Platforms: JOTROL is a proprietary micellar delivery system improving bioavailability.
|
$15.05M |
$0.43
+7.70%
|
|
APLT
Applied Therapeutics, Inc.
ARI platform represents a drug-delivery/targeting platform aiming for tissue-specific penetration, a defined drug-delivery platform category.
|
$14.83M |
$0.11
+4.37%
|
|
COSM
Cosmos Health Inc.
Uses nanoemulsification technology to enhance absorption (e.g., Melatonin Spray), representing a Drug Delivery Platforms capability.
|
$14.19M |
$0.40
-0.69%
|
|
GNTA
Genenta Science S.p.A.
Temferon uses a drug-delivery platform to express payloads in the tumor microenvironment.
|
$13.98M |
$0.71
-1.33%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is described as a self-delivering drug delivery platform for gene silencing.
|
$13.89M |
$1.30
+2.76%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$13.49M |
$2.42
-5.27%
|
|
HOTH
Hoth Therapeutics, Inc.
BioLexa platform and HT-001 formulation imply a drug delivery platform approach (localized/topical delivery).
|
$13.39M |
$1.00
-3.37%
|
|
INTS
Intensity Therapeutics, Inc.
DfuseRx platform and INT230-6.00 involve a drug-delivery platform enabling intratumoral delivery and systemic immune effects.
|
$12.73M |
$5.33
+0.19%
|
|
SNGX
Soligenix, Inc.
Multiple proprietary platforms (HyBryte PDT, IDR, ThermoVax) represent drug delivery platforms.
|
$12.61M |
$1.25
+6.41%
|
|
BCDA
BioCardia, Inc.
Helix is BioCardia's proprietary transendocardial biotherapeutic delivery system, a core drug-delivery platform the company uses to administer its cell therapies.
|
$12.52M |
$1.19
|
|
CLRB
Cellectar Biosciences, Inc.
PDC platform represents a drug delivery platform enabling intracellular payload delivery to tumor cells.
|
$12.38M |
$2.88
-4.32%
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$12.20M |
$0.31
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
Veripure represents a drug-delivery platform for pharmaceutical-grade RBS and PV-10 formulations.
|
$11.47M |
$0.05
|
|
PLRZ
Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
|
$11.18M |
$11.43
+4.48%
|
|
BCAB
BioAtla, Inc.
CAB platform is a conditional antibody/drug delivery platform used to activate drug in tumor microenvironment.
|
$9.65M |
$0.17
+4.02%
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Invisicare-based drug-delivery platform is used for QRX003 and other topical formulations, constituting a major product/technology platform.
|
$9.48M |
$6.42
-2.43%
|
|
NXGL
NEXGEL, Inc.
NXGEL's hydrogel platform enables drug delivery and controlled release applications.
|
$9.28M |
$1.21
+0.42%
|
|
IMNN
Imunon, Inc.
TheraPlas is a drug delivery platform enabling loco-regional cytokine production.
|
$9.10M |
$4.16
+0.73%
|
Showing page 2 of 3 (229 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
